Impax Laboratories Inc. (IPXL)

17.90
0.22 1.24
NYSE : Health Technology
Prev Close 17.68
Open 17.72
Day Low/High 17.50 / 18.29
52 Wk Low/High 13.47 / 18.29
Volume 839.29K
Avg Volume 916.90K
Exchange NYSE
Shares Outstanding 73.87M
Market Cap 1.35B
EPS -6.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Impax Reaches New 52-Week High (IPXL)

Impax Reaches New 52-Week High (IPXL)

Impax Laboratories Incorporated (Nasdaq:IPXL) hit a new 52-week high Thursday as it is currently trading at $28.10, above its previous 52-week high of $28.06 with 214,373 shares traded as of 11:21 a.m. ET. Average volume has been 868,600 shares over the past 30 days.

Impax Laboratories Reports First Quarter 2011 Financial Results

Impax Laboratories Reports First Quarter 2011 Financial Results

Impax Laboratories, Inc. (NASDAQ: IPXL) today reported first quarter ended March 31, 2011 financial results.

Impax Laboratories Appoints Mark A. Schlossberg As Senior Vice President And General Counsel

Impax Laboratories Appoints Mark A. Schlossberg As Senior Vice President And General Counsel

Impax Laboratories, Inc. (NASDAQ: IPXL) announced today the appointment of Mark A.

Impax Laboratories Schedules Conference Call And Webcast For First Quarter 2011 Financial Results

Impax Laboratories Schedules Conference Call And Webcast For First Quarter 2011 Financial Results

Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that its first quarter 2011 financial results will be released before the market opens on Tuesday, May 3, 2011 and will be available on Impax’s Web site at...

Impax Laboratories Confirms Patent Challenge Relating To OXYCONTIN® 10, 15, 20, 30, 40, 60, And 80 Mg

Impax Laboratories Confirms Patent Challenge Relating To OXYCONTIN® 10, 15, 20, 30, 40, 60, And 80 Mg

Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of the patents listed by Purdue Pharma L.

Impax Laboratories Enters Into Commercialization Agreement With Banner Pharmacaps

Impax Laboratories Enters Into Commercialization Agreement With Banner Pharmacaps

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it will collaborate with Banner Pharmacaps Inc.

Impax Laboratories Confirms Patent Challenge Relating To DEXILANT® Delayed-Release Capsules, 30 Mg And 60 Mg

Impax Laboratories Confirms Patent Challenge Relating To DEXILANT® Delayed-Release Capsules, 30 Mg And 60 Mg

Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of patents listed by Takeda Pharmaceutical Company, Ltd.

Impax Stock Hits New 52-Week High (IPXL)

Impax Stock Hits New 52-Week High (IPXL)

Impax Laboratories Incorporated (Nasdaq:IPXL) hit a new 52-week high Monday as it changed hands at $26.25 compared with its previous 52-week high of $26.19. Impax is currently trading at $26.23 with 266,296 shares changing hands as of 11:21 a.m.

Data On IPX066 APEX-PD Phase III Study For The Treatment Of Early Parkinson’s Disease To Be Presented At The American Academy Of Neurology Conference

Data On IPX066 APEX-PD Phase III Study For The Treatment Of Early Parkinson’s Disease To Be Presented At The American Academy Of Neurology Conference

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc.

Impax Stock Hits New 52-Week High (IPXL)

Impax Stock Hits New 52-Week High (IPXL)

Impax Laboratories Incorporated (Nasdaq:IPXL) hit a new 52-week high Tuesday as it changed hands at $25.18 compared with its previous 52-week high of $24.79. Impax is currently trading at $24.45 with 375,492 shares changing hands as of 9:36 a.m.

Impax Labs, Subaye: After-Hours Trading

Impax Labs, Subaye: After-Hours Trading

Impax Laboratories and Subaye were among stocks seeing heavy trading interest in Monday's after-hours action.

Http://www.impaxpharma.com

Http://www.impaxpharma.com

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc.

Impax Laboratories To Present At The Cowen & Co. 31st Annual Health Care Conference

Impax Laboratories To Present At The Cowen & Co. 31st Annual Health Care Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Cowen & Co.

Impax Laboratories Incorporated Stock Upgraded By TheStreet Ratings (IPXL)

Impax Laboratories Incorporated Stock Upgraded By TheStreet Ratings (IPXL)

Impax Laboratories Incorporated (Nasdaq:IPXL) has been upgraded by TheStreet Ratings from a hold to buy.

Impax Laboratories To Present At The RBC Capital Markets’ Healthcare Conference

Impax Laboratories To Present At The RBC Capital Markets’ Healthcare Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the RBC Capital Markets’ Healthcare Conference on Wednesday, March 2, at 1:35 p.

Impax Laboratories Reports Fourth Quarter And Record Full Year 2010 Financial Results

Impax Laboratories Reports Fourth Quarter And Record Full Year 2010 Financial Results

Impax Laboratories, Inc. (NASDAQ: IPXL) today reported fourth quarter and record full year ended December 31, 2010 financial results.

Impax Laboratories Receives Final FDA Approval For Generic Adoxa® 150 Mg Capsules

Impax Laboratories Receives Final FDA Approval For Generic Adoxa® 150 Mg Capsules

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the U.

Impax Stock Hits New 52-Week High (IPXL)

Impax Stock Hits New 52-Week High (IPXL)

Impax Laboratories Incorporated (Nasdaq:IPXL) hit a new 52-week high Tuesday as it changed hands at $24.68 compared with its previous 52-week high of $24.66. Impax is currently trading at $24.67 with 172,809 shares changing hands as of 10:26 a.m..

Impax Laboratories Schedules Conference Call And Webcast For Fourth Quarter And Full Year 2010 Financial Results

Impax Laboratories Schedules Conference Call And Webcast For Fourth Quarter And Full Year 2010 Financial Results

Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that its fourth quarter and full year 2010 financial results will be released before the market opens on Thursday, February 24, 2011 and will be available on...

Impax Laboratories Corrects Inaccurate Information About Product Pipeline Opportunities Discussed In Several Financial Articles Circulated On The Internet

Impax Laboratories Corrects Inaccurate Information About Product Pipeline Opportunities Discussed In Several Financial Articles Circulated On The Internet

Impax Laboratories, Inc. (NASDAQ: IPXL) today commented on inaccurate and misleading information about its generic product pipeline that appears in several financial articles circulated on numerous financial websites.

5 Bargain Biotech Stocks

5 Bargain Biotech Stocks

Life-saving companies such as Cerus and Curis could mean life-changing wealth for investors.

Impax Laboratories To Present At The J.P. Morgan Annual Healthcare Conference

Impax Laboratories To Present At The J.P. Morgan Annual Healthcare Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the J.

Goldman Sachs, Morgan: Premarket Trading

Goldman Sachs, Morgan: Premarket Trading

Calyon Securities analyst Mike Mayo lowers his earnings estimates for Goldman Sachs and Morgan Stanley on worries about the weakness in rates products.

Impax Laboratories Receives Final FDA Approval For Generic Doryx® 75 And 100mg Tablets

Impax Laboratories Receives Final FDA Approval For Generic Doryx® 75 And 100mg Tablets

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the U.

GlaxoSmithKline And Impax Pharmaceuticals Enter Global Agreement To Develop And Commercialize A Late Stage Compound For Parkinson’s Disease

GlaxoSmithKline And Impax Pharmaceuticals Enter Global Agreement To Develop And Commercialize A Late Stage Compound For Parkinson’s Disease

GlaxoSmithKline (GSK) and Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc.

Impax Laboratories Confirms Patent Challenge Relating To INTUNIVTM, 4 Mg

Impax Laboratories Confirms Patent Challenge Relating To INTUNIVTM, 4 Mg

Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of patents listed by Shire Development Inc.

Impax Laboratories Confirms Patent Suit Relating To Generic Concerta® 54 Mg Tablets

Impax Laboratories Confirms Patent Suit Relating To Generic Concerta® 54 Mg Tablets

Impax Laboratories, Inc. (NASDAQ:IPXL) today confirms that Alza Corporation has filed suit for patent infringement against Impax in the United States District Court for the District of Delaware in connection with...

Impax Laboratories To Present At The Piper Jaffray Annual Healthcare Conference

Impax Laboratories To Present At The Piper Jaffray Annual Healthcare Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Piper Jaffray 22nd Annual Healthcare Conference on Wednesday, December 1, at 12:30 p.

Impax Laboratories Confirms Patent Challenge Relating To SIMCOR® Extended-Release Tablets, 1000/20 Mg

Impax Laboratories Confirms Patent Challenge Relating To SIMCOR® Extended-Release Tablets, 1000/20 Mg

Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of patents listed in connection with SIMCOR ® (niacin/simvastatin) extended-release tablets, 1000/20 mg.

Impax Confirms Patent Challenge Relating To WELCHOL® For Oral Suspension, 3.75 Gm/packet And 1.875 Gm/packet

Impax Confirms Patent Challenge Relating To WELCHOL® For Oral Suspension, 3.75 Gm/packet And 1.875 Gm/packet

Impax Laboratories, Inc. (NASDAQ:IPXL) today confirms that it has initiated a challenge of patents listed by Daiichi Sankyo, Inc.